drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous peripheral blood T cells expanded and activated ex vivo to recognize MUC1 via TCR; infused intravenously as adoptive cellular immunotherapy to mediate tumor cell killing and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Activated
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous peripheral blood T cells are expanded ex vivo and enriched/activated for TCR-mediated recognition of MUC1 peptides presented on MHC. After infusion, these MUC1‑reactive T cells engage tumor cells, become activated, and mediate cytotoxicity via perforin/granzyme release and cytokine secretion (e.g., IFN-γ, TNF), leading to targeted tumor cell killing and immune amplification.
drug_name
Autologous MUC1-activated T cells
nct_id_drug_ref
NCT06483048